Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GBT440 in Renal Impairment
NCT03161015Phase 1Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of voxelotor in sickle cell disease (SCD) (4 arms), sponsored by Global Blood Therapeutics. Primary endpoints: Maximum Plasma Concentration at 28 days, Time to Maximum Plasma Concentration at 28 days and 2 more. Started Nov 2016; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03161015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161015.